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Abstract
Pre-exposure prophylaxis (PrEP) can reduce U.S. HIV incidence. We assessed insurance
coverage and its association with PrEP utilization. We reviewed patient data at three PrEP
clinics (Jackson, Mississippi; St. Louis, Missouri; Providence, Rhode Island) from 2014–
2015. The outcome, PrEP utilization, was defined as patient PrEP use at three months. Mul-
tivariable logistic regression was performed to determine the association between insurance
coverage and PrEP utilization. Of 201 patients (Jackson: 34%; St. Louis: 28%; Providence:
28%), 91% were male, 51% were White, median age was 29 years, and 21% were unin-
sured; 82% of patients reported taking PrEP at three months. Insurance coverage was sig-
nificantly associated with PrEP utilization. After adjusting for Medicaid-expansion and
individual socio-demographics, insured patients were four times as likely to use PrEP ser-
vices compared to the uninsured (OR: 4.49, 95% CI: 1.68–12.01; p = 0.003). Disparities in
insurance coverage are important considerations in implementation programs and may
impede PrEP utilization.
Introduction
In 2014, over 40,000 individuals were diagnosed with human immunodeficiency virus (HIV)
infection in the United States (US) with the majority among men who have sex with men
(MSM) [1]. There are large disparities in HIV incidence, with African Americans facing a dis-
proportionate burden of new infections [1]. Pre-exposure prophylaxis (PrEP) refers to the use of
antiretrovirals to prevent HIV infection prior to exposure. It is estimated that over 1.2 million
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adults in the US are at risk for HIV and would benefit from PrEP [2]. Taken as a daily single oral
tablet, PrEP has been proven to prevent HIV infection in MSM and other populations [3,4].
PrEP implementation has become a national priority to reduce new HIV infections [5,6].
One potential barrier to wider PrEP use in the US is insurance coverage. Insurance cover-
age usually leads to increased access to healthcare and use of healthcare services [7]. However,
17.9% of adults ages 25–34 years were uninsured in 2015, despite the passage of the Affordable
Care Act [8]. Few studies have evaluated whether insurance coverage impacts PrEP care [5].
We previously evaluated retention-in-care outcomes among patients enrolled in PrEP pro-
grams in three US cities; insurance was not found to affect PrEP care and retention among a
subanalysis of MSM at these sites [9]. Recent data from participants in the US PrEP Demon-
stration Project showed that individuals who were non-white, uninsured, and of lower socio-
economic status reported barriers to accessing PrEP after the Demonstration Project ended
[10]. White participants, in addition to those with health insurance, higher education, older
age, and reported willingness to pay more for PrEP, were more likely to have continued PrEP
after study completion [10]. These differences in PrEP use by race and socioeconomic status
could potentially exacerbate existing disparities in HIV incidence.
To further explore the impact of insurance coverage on PrEP utilization in the US, we eval-
uated whether insurance status was associated with PrEP utilization among patients prescribed
PrEP at clinics in three states with varied Medicaid expansion [11].
Methods
We reviewed patients in clinical PrEP programs in Providence, Rhode Island, Jackson, Missis-
sippi and St. Louis, Missouri from January 2014 to December 2015. In Rhode Island, PrEP
patients were seen at a sexually transmitted diseases and HIV prevention clinic that was aca-
demically affiliated; patients were referred to the clinic from an onsite HIV clinic and other
providers [9]. In Mississippi, PrEP patients were seen at a lesbian/gay/bisexual/transgender
outpatient clinic; patients were referred from other providers and the state sexually transmitted
diseases clinic [9]. In Missouri, PrEP patients were seen at an academic infectious diseases spe-
cialty clinic; referrals to this clinic were from community-based organizations, local outpatient
providers, and an onsite HIV clinic [9]. All three sites were the major outpatient PrEP provid-
ers in their respective states. This analysis was a sub-study of an ongoing prospective observa-
tional cohort [9]. Inclusion criteria were patients who were prescribed PrEP for at least three
months. Demographic and insurance-related information was collected during clinical visits
as part of routine patient care procedures and data was extracted from the electronic medical
records. Demographic data included age, gender, race, ethnicity, education, income, and
insurance type. Insurance type included having no insurance or having private or public insur-
ance (i.e. government-funded) [9].
As a part of the Affordable Care Act, state governments could choose to expand Medicaid
eligibility to those with annual incomes below 138% of the federal poverty level [12]. Nineteen
U.S. states have not yet expanded Medicaid. At the time of this study, Rhode Island was the
only Medicaid-expansion state among our three sites. We created an indicator variable for
state Medicaid expansion and grouped study states according to this status. Insurance status
was further categorized by whether patients who had either private or public insurance. Private
insurance included individual or group commercial insurance. Public insurance was defined
as Medicaid, Medicare, or another public insurance program.
This study was approved by the Institutional Review Boards at Washington University in
St. Louis, University of Mississippi, and The Miriam Hospital for human subject’s research. All
participants provided written informed consent.
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Statistical analysis
The primary outcome was PrEP utilization, defined as patient report of taking PrEP at their
three-month follow-up evaluation. Evaluations were performed in person as part of a routine
clinical care visit or over the phone, when a physical appointment was not possible; routine
clinical care was administered as per national guidelines [9]. Independent variables included
age, race, education, income, insurance status, state Medicaid expansion, and study site. We
created a Medicaid state expansion variable to account for the fact that in states with Medicaid
expansion, it may be easier to acquire insurance, which may affect care utilization [13,14]. The
association between independent variables and the outcome was assessed using chi-square or
Fisher’s exact tests. To investigate factors predicting the primary outcome, univariate and mul-
tivariate logistic regression models were used. Odds ratios (OR) and 95% confidence intervals
(CI) were calculated. We assessed the impact of insurance on PrEP utilization using a multi-
variable logistic regression Model 1 and adjusted for age, race, education, income, and individ-
ual insurance coverage. In subsequent models, we also assessed how insurance was affected by
the addition of state Medicaid expansion (Model 2) and study site (Model 3). We accounted
for Medicaid expansion since this affects the ability to obtain insurance for people within spe-
cific states. To control for the study site within the analysis, we looked at study site in two
ways: 1) with Mississippi as a referent (versus Missouri and Rhode Island) and 2) with each
state separately with Rhode Island as a referent. All statistical tests were two-sided and the sig-
nificance level was set at 0.05.
Results
Overall, 201 PrEP patients were included into the analysis (33.8% from Mississippi, 27.9%
from Missouri, and 38.3% from Rhode Island). Eighty-two percent of patients reported taking
PrEP at three months.
Patient characteristics included median age of 29 years (Interquartile Range [IQR] 24–37),
91.0% were male, 51.2% were white, 34.3% were African American, 6.0% were Latino, 64.7%
were college graduates, 79.1% had either public or private insurance, and median income was
$25,000 (IQR $7,200-$50,000) (Table 1). Almost all patients (95%) were insured in Providence,
49% in Jackson and 95% in St. Louis (P<0.01).
Univariate and multivariate logistic regression analyses are shown in Table 2. In the initial
multivariate logistic regression analysis model (Model 1), which included age, race, education,
income and individual insurance coverage, having insurance was significantly and positively
associated with PrEP utilization (OR = 3.48, 95% CI: 1.39–8.69). Insurance remained signifi-
cant when adjusting for state Medicaid expansion (Model 2) as well as for study site (Model 3)
(OR = 4.49, 95% CI: 1.68–12.01 and OR = 3.98, 95% CI: 1.36–11.63, respectively). None of the
other independent variables were found to be significant predictors. When looking at the effect
of the study site using Jackson, Mississippi as a referent on the outcome, there were no signifi-
cant findings in univariate or multivariate analysis (i.e. adjusting for demographics, insurance,
and study site) (unadjusted OR = 1.74, 95% CI: 0.83–3.63 and adjusted OR = 0.79, 95% CI:
0.29–2.18). The significance of insurance was not affected by this re-categorization of study
site using Jackson, Mississippi as the referent (OR = 4.15, 95% CI: 1.49–11.59).
Discussion
We found that having insurance coverage may significantly impact PrEP utilization. Insured
patients in our sample were four times as likely to use PrEP services compared to the unin-
sured. Our results should be taken into the context that nearly one out of five young adults are
uninsured and that national HIV burden is highest in the southern US, where non-Medicaid
PrEP and insurance coverage
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expansion limits insurance coverage eligibility [1,8]. Furthermore, in the context of upcoming
proposed changes to the healthcare system, our findings indicate that there could be potential
setbacks in PrEP implementation if reforms make accessing insurance more difficult [14,15].
The proposed American Health Care Act would cause 14 million people to lose their insurance
in 2018 and 24 million over the next decade [15,16]. Specific reforms include changing the fed-
eral match for Medicaid to a block grant policy where the government caps the amount of
money allotted per Medicaid enrollee and would match only 50% of costs per enrollee versus
the 90% under the Affordable Care Act [14,15]. This change in Medicaid policy would cause
17 million Americans to lose their insurance within 10 years. Other reforms that have the
potential to change insurance access or quality of coverage to pay for PrEP-related care and
costs for young adults, a group with high HIV incidence, include changing a mandate for
employers to provide insurance as well as a $7 billion reduction in federal subsidies to reduce
deducible and copayment costs for care for enrollees. Inadequate insurance coverage for at-
Table 1. Study population characteristics (N = 201).
Characteristic Missed 3-month Appointment N = 36 Attended 3-month Appointment N = 165 P value
Gender 0.34†
Male 31 (86.1) 152 (92.1)
Female 5 (13.9) 12 (7.3)
Transgender 0 (0.0) 1 (0.6)
Age (Years) 0.02
18–24 15 (41.7) 36 (31.8)
25–34 9 (25.0) 75 (45.5)
>34 12 (33.3) 54 (32.7)
Race 0.09†
White 15 (41.7) 88 (53.3)
African American 18 (50.0) 51 (30.9)
Latino 0 (0.0) 12 (7.3)
Mixed/Other 3 (8.3) 14 (8.5)
Education 0.91
< College 13 (36.1) 58 (35.2)
 College 23 (63.9) 107 (64.8)
Income 0.13
< $25000 22 (61.1) 78 (47.3)
 $25000 14 (38.9) 87 (52.7)
Insurance 0.003
None 15 (41.7) 27 (16.4)
Public 4 (11.1) 24 (14.5)
Private 17 (47.2) 114 (69.1)
State Medicaid Expansion* 0.65
No 21 (58.3) 103 (62.4)
Yes 15 (41.7) 62 (37.6)
Site 0.10
Providence 15 (41.7) 62 (37.6)
St. Louis 5 (13.9) 51 (30.9)
Jackson 16 (44.4) 52 (31.5)
†Fisher’s Exact Test
*Medicaid Expansion State: Rhode Island
https://doi.org/10.1371/journal.pone.0178737.t001
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risk individuals undermines the goal of reducing HIV incidence through PrEP and other pre-
ventative care.
Since Medicaid eligibility expansion increases the ability to obtain insurance despite varia-
tions in patient backgrounds (i.e. race, income, age, etc.), we evaluated this concept within our
analysis. In this sample, adjusting for Medicaid expansion using multiple logistic regression
did not diminish insurance coverage’s association with PrEP utilization. This study is limited
by the inclusion of only one Medicaid expansion state; however our analyses highlighted pri-
vate insurance’s effect on PrEP utilization given the effect of insurance remained significant
after controlling separately for Medicaid expansion status in the model. Further larger studies
should explore Medicaid expansion’s impact on PrEP use. Such findings could help influence
retaining stronger preventive care policies within the context of today’s health care policy
reforms.
Prior studies have demonstrated that insurance coverage influences PrEP care [5,10].
Among patients in The Demo Project in San Francisco, 11.8% discontinued PrEP due to leav-
ing their health plan. Prior work has demonstrated that a significant facilitator to PrEP uptake
is free access [17]. A modeling study conducted in Georgia, a Medicaid non-expansion state,
among 562 MSM predicted that only 15% of MSM would achieve protection from HIV by
Table 2. Univariate and multivariate logistic regression analysis for HIV pre-exposure prophylaxis utilization among 201 patients in three US cities
(Jackson, Mississippi; St. Louis, Missouri; Providence, Rhode Island) from January 2014 to December 2015.
Characteristic Unadjusted OR (95% CI) Model 1* aOR (95% CI) Model 2** aOR (95% CI) Model 3*** aOR (95% CI)
Age Group
< 30 years 1.0 1.0 1.0 1.0
 30 years 1.21 (0.58–2.49) 0.92 (0.41–2.10) 0.95 (0.41–2.18) 0.95 (0.41–2.19)
Race
White 1.0 1.0 1.0 1.0
Not White 0.63 (0.30–1.30) 0.99 (0.40–2.47) 0.86 (0.34–2.19) 0.90 (0.35–2.35)
Education
< College 1.0 1.0 1.0 1.0
 College 1.04 (0.49–2.21) 0.87 (0.38–1.98) 0.81 (0.36–1.85) 0.82 (0.36–1.88)
Income
< $25000 1.0 1.0 1.0 1.0
 $25000 1.75 (0.84–3.66) 1.19 (0.49–2.90) 1.23 (0.50–3.00) 1.21 (0.50–2.97)
Insurance
No 1.0 1.0 1.0 1.0
Yes (public or private) 3.65 (1.67–7.97) 3.48 (1.39–8.69) 4.49 (1.68–12.01) 3.98 (1.36–11.63)
State Medicaid Expansion†
No 1.0 - 1.0 -
Yes 0.84 (0.41–1.76) - 0.46 (0.19–1.10) -
Site
Providence 1.0 - - 1.0
St. Louis 2.47 (0.84–7.25) - - 2.58 (0.86–7.70)
Jackson 0.79 (0.36–1.74) - - 1.82 (0.62–5.38)
Abbreviations: OR, odds ratio; aOR, adjusted OR
*Adjusted for age, race, education, income, and individual insurance coverage
**Adjusted for age, race, education, income, individual insurance coverage, and state Medicaid expansion
***Adjusted for age, race, education, income, individual insurance coverage, and study site
†Medicaid Expansion State: Rhode Island
https://doi.org/10.1371/journal.pone.0178737.t002
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using PrEP largely due to significant barriers to health care access, which was defined as receiv-
ing a prescription and paying provider visits and laboratory-related costs [18]. Although the
manufacturer of PrEP, Gilead Sciences, has a patient drug assistance program, the current
study demonstrates that ongoing structural gaps may impede PrEP use by those who might
benefit most [19]. The findings are particularly notable, given that the patients in this study
received care in specialized clinics, with staff available to help them navigate the paperwork
needed to access insurance and/or medication.
Limitations of the study include a small sample size, a large portion of uninsured patients
came from one site (MS), and that insurance coverage was examined at one time point (i.e. ini-
tial evaluation). Future studies should include other clinical settings, rural populations, more
states with varying Medicaid expansion, a method to capture insurance mobility, and evaluate
insurance coverage’s effects on other aspects of PrEP care. Examining these factors will provide
important insights for PrEP program planners, policy makers, and others on how to effectively
improve PrEP implementation, especially for individuals with financial barriers and who lack
insurance.
Insurance coverage had a significant and positive impact on PrEP utilization. Disparities in
insurance coverage may impede PrEP implementation in non-trial clinical settings and may
exacerbate disparities in PrEP access. These findings from three diverse areas suggest state-
and local-level PrEP implementation efforts should address barriers to insurance coverage as a
critical component to successful programmatic efforts.
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